If you know the name Invigor Medical, its main website now leads to Try Invigor. The current NAD+ injection page advertises a starting price of $340 per month, including a doctor consultation and supplies. This review follows that current offer rather than carrying forward an older price from a search result.
Our September 19, 2026 research covered the public treatment page and sales terms. We did not buy a plan, inspect a medication shipment, or verify a laboratory report. The review focuses on what the stated bundle includes, what remains unclear, and which questions help compare it with lower-priced online offers.
The current offer starts at $340 monthly and describes clinical review, supplies, and support. Request the actual quantity, complete renewal quote, and preparation-specific quality documentation.
Confirm the current offer and business name
The Invigor Medical homepage redirected to Try Invigor, whose NAD+ injection page displayed the current starting price. That redirect is useful context for readers encountering both names. It does not mean every older blog post or archived offer describes today’s order.
Check that the service name, contact details, prescription paperwork, and payment terms fit together before paying. If support sends a different quote from the public page, ask which preparation and services explain the difference. Keeping the dated offer alongside the written quote is a simple way to avoid comparing an old promotion with a current plan.
What is included in the $340 starting figure?
The treatment page lists a consultation, medication and supplies, and access to support. It describes provider review followed by pharmacy shipment. Those are advertised inclusions; we have not verified a completed invoice or a universal supply quantity that would let us calculate an equivalent cost per prescribed treatment across competitors.
Ask for the actual vial details, expected supply period, and amount due for the next order. Also confirm whether shipping, required testing, or a later visit adds to the total. Our cost guide explains why a higher price does not by itself establish a larger supply, better care, or superior treatment results.
Clarify the consultation and follow-up
A consultation is valuable when it gives you a chance to describe the concern, discuss alternatives, and understand the plan. Ask whether your initial review involves a live conversation, written communication, or both. Find out how to arrange a discussion if an intake form does not capture your situation.
The page’s support language does not establish a guaranteed response time for every type of question. Confirm who handles medication concerns after delivery and how the service distinguishes routine messaging from symptoms that need urgent assessment. Readers who prefer a phone call can make that preference part of the decision before enrollment.
What the public quality display can tell you
Invigor states that its partner pharmacies use third-party laboratory checks. The reviewed page displayed testing cards with a placeholder-style date of 01-01-01. Those cards were not a patient-specific or lot-matched laboratory report we could authenticate. We therefore do not describe the medication you might receive as independently verified by this review.
Ask which pharmacy would dispense your preparation and whether supporting information identifies the relevant product, lot, methods, and test date. Our pharmacy-verification guide explains the distinction between a general quality statement and records that apply to a specific supply. Either still differs from FDA approval of a finished drug.
Read the sales terms with the plan price
The published sales terms identify Ikon Health LLC doing business as Try Invigor and discuss availability, possible price corrections, and applicable taxes or shipping charges. Those general terms should be reconciled with the inclusions quoted for your chosen plan. The reviewed policy carries a March 2023 update date.
Before ordering, ask when a payment becomes nonrefundable and how to stop future purchases. Do not infer that an advertised flexible plan means a processed prescription can be reversed. A clear written answer should cover both a voluntary cancellation and a clinician deciding the treatment is unsuitable after reviewing your history.
Benefits require more than testimonials
The treatment page uses customer accounts and discussions of NAD biology to describe potential benefits. Neither establishes how its compounded injection performs for a person with your symptoms. The NAD+ evidence guide is a better starting point for separating research questions from an expectation of restored energy or sharper memory.
Compounded NAD+ is not FDA-approved, and FDA has raised ingredient-quality concerns about injectable NAD+ products generally. Discuss the reason for treatment, possible risks, and a plan for reassessment with the prescriber. Persistent fatigue deserves evaluation rather than an automatic assumption that a marketed longevity treatment is the missing ingredient.
How to compare Invigor fairly
For another recurring injection offer, read the Strut Health review. For a service with a broader membership structure, see our Hone review. Compare a written total and the support you would use; an apparent price gap may reflect different quantities, billing periods, or included services.
The CoreAge Rx review covers our featured commercial partner and its unresolved public price difference. We do not infer that either a premium price or a promotional first position predicts a better medical outcome. Use the consultation checklist to request comparable answers from each provider.
Follow the source
References & further reading
- Try Invigor — NAD+ injection plan
Current provider offer reviewed September 19, 2026. Generic test displays are not independently authenticated lot-specific reports.
- Invigor Medical — current website and branding
The homepage redirected to Try Invigor during the September 19, 2026 research pass.
- Try Invigor — sales and refund terms
Published terms reviewed September 19, 2026; page displays a March 27, 2023 update date. Confirm terms for the selected plan.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- NABP — boards of pharmacy
Find the pharmacy regulator for your state.